Application of Poloxamers for the Development of Drug Delivery System to Treat Leishmaniasis: A Review

Author(s): Audrey Silva, Amanda Costa, Sona Jain, Eduardo Coelho, Ricardo Fujiwara, Ricardo Scher, Rogéria Nunes, Silvio Dolabella*

Journal Name: Current Drug Targets

Volume 22 , Issue 3 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Leishmaniasis is a neglected tropical disease affecting more than 1.5 million people annually, with an annual mortality of over 20.000. The drugs used for its treatment are toxic, expensive, require extended treatment times and present variable efficacy. The disease severity and therapy limitations suggest the need for new antileishmanial agents. In this context, in order to identify new options for treatment, a number of studies based on nanotechnological strategies have been carried out. Poloxamers are triblock copolymers very often utilized for nanotherapeutic solutions, resulting in products with better solubility, higher stability, superior therapeutic efficacy and less toxicity. This review will discuss the physicochemical properties of the copolymers, as well as describe the use of poloxamers for the development of therapeutic formulations to treat leishmaniasis.

Keywords: Pluronic, triblock copolymers, nanotechnology, leishmania, treatment, chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 3
Year: 2021
Published on: 17 February, 2021
Page: [296 - 309]
Pages: 14
DOI: 10.2174/1389450121666201106145022
Price: $65

Article Metrics

PDF: 12